Researchers in the lab of Dr. Robert O. (Bill) Williams III, Division Head and Professor of Molecular Pharmaceutics and Drug Delivery at the College of Pharmacy, are advancing an innovative platform technology known as Thin Film Freezing, which could revolutionize administration, distribution and access to both vaccines and therapies.
P4 students, Megan Yeung, Kami Johnston and Morgan Murchison co-author a peer-reviewed blog in Pulses encouraging educators to adapt to reflect the specific needs of people who use drugs and patients with substance use disorders. This blog also highlights UT Pharmacy as a U.S. leader in substance use disorder and harm reduction education for Pharm.D. students.
Tara Law from Time writes about how few pharmacies carry buprenorphine, a life-saving drug to help treat opioid use disorder (OUD). Lucas Hill, Pharm.D., BCACP, director of the college's Pharmacy Addictions Research & Medicine (PhARM) program, offers his insight on the issue, and how the DEA's crackdown of the drug puts OUD patients at risk.
A paper from UT College of Pharmacy researchers was awarded the 2021 Outstanding Paper of the Year from the American College of Clinical Pharmacy (ACCP) Ambulatory Care Practice Research Network. The paper investigates the availability of buprenorphine and naloxone in Texas to treat opioid use disorder.
UT Pharmacy and UT Health Science Center San Antonio Assistant Professor Grace C. Lee, Pharm.D., Ph.D. is the first author of a recently published study that unveiled a novel concept, “immunologic resilience,” to accurately predict which COVID-19 patients will advance to severe disease and which will not.
Division Head and Professor of Molecular Pharmaceutics and Drug Delivery Dr. Bill Williams was on KXAN News to talk about promising new data from TFF Pharmaceuticals and Augmenta Bioworks. The companies plan to develop Dr. Williams' thin film freezing technology to better deliver antibody treatment directly to the lungs of COVID patients.
Molecular Pharmaceutics and Drug Delivery Professor Robert O. (Bill) Williams III, Ph.D. talks to CBS Austin about the potential for his thin film freezing technology to increase the shelf life of COVID-19 vaccines when they become available.
Live subject testing results from the Williams Lab show that dry powder inhalation could be a potent and effective delivery method of the antiviral remdesivir to treat patients affected by COVID-19.
A team of researchers in the college, led by Robert O. (Bill) Williams III and Hugh D. Smyth, is investigating varying methods of drug delivery to repurpose existing drugs in order to treat and prevent serious COVID-19 virus symptoms in patients.
Professor Rueben Gonzales of the Department of Pharmacology and Toxicology was named a fellow of the American Association for the Advancement of Science (AAAS) for distinguished contributions to the field of alcohol research.
